Dr. Shirasu on the Utilization of ctDNA Testing in CRC

Video

Hiromichi Shirasu, MD, discusses the utilization of circulating tumor DNA testing in colorectal cancer.

Hiromichi Shirasu, MD, senior staff member, Division of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan, discusses the utilization of circulating tumor DNA (ctDNA) testing in colorectal cancer (CRC). 

The GALAXY trial (UMIN000039205), part of the CIRCULATE-Japan project, is an ongoingstudy monitoring ctDNA in patients with resectable CRC, Shirasu says. The Signatera™ assay is a novel, patient-specific, custom-built ctDNA test that detects minimal residual disease in the plasma, Shirasu explains. The assay tests for 16 patient-specific, somatic, single-nucleotide variants, Shirasu continues.

Via whole-exome sequencing of the tumor tissue, the assay is highly specific and sensitive based on a variant-allele frequency of 0.01%, Shirasu concludes. 

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute